Evidence map›Paper›PMID 20648364›Full record

ReviewNanoscale2010

Quantum dot-based theranostics.

Yi-Ping Ho, Kam W Leong

Abstract readReview
In one paragraph

Review in Nanoscale, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Applications of Quantum Dots in Preventive Oncology.Asian Pacific journal of cancer prevention : APJCP · 2024
    Review
  5. Review
  6. Micro and nanotechnologies: The little formulations that could.Bioengineering & translational medicine · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Diagnostic and Therapeutic Nanomedicine.Advances in experimental medicine and biology · 2021
    Article
  12. Introduction of Nanobiotechnology.Advances in experimental medicine and biology · 2021
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. CaCOMaterials (Basel, Switzerland) · 2019
    Article
  19. State-of-the-Art and Trends in Synthesis, Properties, and Application of Quantum Dots-Based Nanomaterials.Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yi-Ping HoDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Kam W Leong

Funding

Oral Nonviral Gene Delivery for Hemophilla AR01HL089764 · NHLBI · DUKE UNIVERSITY · PI LEONG, KAM W · 2008 to 2011
$1.7M
Mechanistic Studies on Polymeric Controlled Oral GeneR01EB002849 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI LEONG, KAM W · 2003 to 2007
$1.3M
NHLBI NIH HHS HL89764NHLBI NIH HHS R01 HL089764NIBIB NIH HHS EB002849NIBIB NIH HHS R01 EB002849
6 · The paper itself

Abstract

Luminescent semiconductor nanocrystals, also known as quantum dots (QDs), have advanced the fields of molecular diagnostics and nanotherapeutics. Much of the initial progress for QDs in biology and medicine has focused on developing new biosensing formats to push the limit of detection sensitivity. Nevertheless, QDs can be more than passive bio-probes or labels for biological imaging and cellular studies. The high surface-to-volume ratio of QDs enables the construction of a "smart" multifunctional nanoplatform, where the QDs serve not only as an imaging agent but also a nanoscaffold catering for therapeutic and diagnostic (theranostic) modalities. This mini review highlights the emerging applications of functionalized QDs as fluorescence contrast agents for imaging or as nanoscale vehicles for delivery of therapeutics, with special attention paid to the promise and challenges towards QD-based theranostics.

Indexed as

Quantum DotsAptamers, NucleotideContrast MediaDrug CarriersFluorescence Resonance Energy TransferHumansMicroscopy, FluorescencePharmaceutical PreparationsAptamers, NucleotideContrast MediaDrug CarriersPharmaceutical Preparations

Identifiers

PMID20648364
PMCPMC2965651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.